Jason M. Pogue

10.1k total citations · 2 hit papers
155 papers, 6.4k citations indexed

About

Jason M. Pogue is a scholar working on Molecular Medicine, Pharmacology and Applied Microbiology and Biotechnology. According to data from OpenAlex, Jason M. Pogue has authored 155 papers receiving a total of 6.4k indexed citations (citations by other indexed papers that have themselves been cited), including 89 papers in Molecular Medicine, 70 papers in Pharmacology and 63 papers in Applied Microbiology and Biotechnology. Recurrent topics in Jason M. Pogue's work include Antibiotic Resistance in Bacteria (89 papers), Antibiotics Pharmacokinetics and Efficacy (69 papers) and Antibiotic Use and Resistance (63 papers). Jason M. Pogue is often cited by papers focused on Antibiotic Resistance in Bacteria (89 papers), Antibiotics Pharmacokinetics and Efficacy (69 papers) and Antibiotic Use and Resistance (63 papers). Jason M. Pogue collaborates with scholars based in United States, Israel and Australia. Jason M. Pogue's co-authors include Keith S. Kaye, Erin K. McCreary, Ryan P. Mynatt, Paul Lephart, Michael J. Rybak, Dror Marchaim, Teena Chopra, Jian Li, Kerry L. LaPlante and Haley J. Morrill and has published in prestigious journals such as SHILAP Revista de lepidopterología, Clinical Microbiology Reviews and Clinical Infectious Diseases.

In The Last Decade

Jason M. Pogue

145 papers receiving 6.3k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti‐infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP)

2019 637 citations Brian T. Tsuji, Jason M. Pogue et al. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy profile →
Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial

2020 319 citations Richard G. Wunderink, Keith S. Kaye et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jason M. Pogue United States	42	3.8k	2.9k	1.9k	1.6k	1.5k	155	6.4k
Ryan K. Shields United States	49	4.7k 1.2×	3.3k 1.1×	3.1k 1.7×	1.6k 1.0×	2.1k 1.5×	199	7.4k
George L. Daikos Greece	40	4.5k 1.2×	2.4k 0.8×	2.1k 1.1×	1.4k 0.9×	763 0.5×	136	6.8k
Teresa Spanu Italy	43	3.5k 0.9×	1.4k 0.5×	2.3k 1.2×	1.4k 0.9×	1.4k 1.0×	130	6.5k
Philippe Lagacé‐Wiens Canada	38	2.9k 0.8×	1.8k 0.6×	1.7k 0.9×	922 0.6×	1.3k 0.9×	126	5.3k
Murat Akova Türkiye	39	2.8k 0.7×	1.6k 0.6×	2.7k 1.5×	894 0.6×	2.0k 1.4×	151	6.9k
Douglas J. Biedenbach United States	44	2.9k 0.8×	1.9k 0.6×	2.0k 1.1×	1.2k 0.7×	2.2k 1.5×	153	6.1k
Vincent H. Tam United States	50	5.5k 1.5×	4.9k 1.7×	2.8k 1.5×	1.8k 1.1×	1.3k 0.9×	192	8.7k
Enrico Maria Trecarichi Italy	38	2.8k 0.7×	1.3k 0.5×	2.3k 1.2×	1.3k 0.8×	1.8k 1.2×	113	5.9k
Heather J. Adam Canada	38	2.8k 0.7×	1.8k 0.6×	2.1k 1.1×	884 0.6×	1.3k 0.9×	144	5.5k
John Quale United States	40	4.7k 1.2×	2.2k 0.8×	1.5k 0.8×	1.4k 0.9×	1.4k 0.9×	108	6.6k

Countries citing papers authored by Jason M. Pogue

Since Specialization

Citations

This map shows the geographic impact of Jason M. Pogue's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jason M. Pogue with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jason M. Pogue more than expected).

Fields of papers citing papers by Jason M. Pogue

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jason M. Pogue. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jason M. Pogue. The network helps show where Jason M. Pogue may publish in the future.

Co-authorship network of co-authors of Jason M. Pogue

This figure shows the co-authorship network connecting the top 25 collaborators of Jason M. Pogue. A scholar is included among the top collaborators of Jason M. Pogue based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jason M. Pogue. Jason M. Pogue is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Horcajada, Juan Pablo, Ana Cristina Gales, Burcu Isler, et al.. (2025). Current and future options for the treatment of serious infections due to carbapenem-resistant Pseudomonas aeruginosa. Clinical Microbiology Reviews. 38(4). e0023324–e0023324.

Aitken, Samuel L, et al.. (2025). First Report of Treatment-Emergent Resistance to Cefepime-Zidebactam in Pseudomonas aeruginosa. Clinical Infectious Diseases. 82(1). 44–48.

Shah, Sunish, Ellen G Kline, Ghady Haidar, et al.. (2024). Rates of Resistance to Ceftazidime-Avibactam and Ceftolozane-Tazobactam Among Patients Treated for Multidrug-Resistant Pseudomonas aeruginosa Bacteremia or Pneumonia. Clinical Infectious Diseases. 80(1). 24–28. 9 indexed citations

Aitken, Samuel L, et al.. (2024). A Comparison of Different Strategies for Optimizing the Selection of Empiric Antibiotic Therapy for Pneumonia Caused by Gram-Negative Bacteria in Intensive Care Units: Unit-Specific Combination Antibiograms Versus Patient-Specific Risk Factors. Open Forum Infectious Diseases. 11(11). ofae643–ofae643. 1 indexed citations

Pogue, Jason M., et al.. (2024). Tebipenem and Sulopenem: Dynamic Duo or Double Trouble?. Current Infectious Disease Reports. 26(5). 139–150. 7 indexed citations

Mynatt, Ryan P., et al.. (2023). Clinical Outcomes With Extended Versus Intermittent Infusion of Anti-Pseudomonal Beta-Lactams in Patients With Gram-Negative Bacteremia. Open Forum Infectious Diseases. 10(4). ofad170–ofad170. 9 indexed citations

Rao, Krishna, J.N.B. Bell, Oryan Henig, et al.. (2023). An Open-Label, Randomized Trial Comparing Fidaxomicin With Oral Vancomycin for the Treatment of Clostridioides difficile Infection in Hospitalized Patients Receiving Concomitant Antibiotics for Concurrent Infections. Clinical Infectious Diseases. 78(2). 277–282. 9 indexed citations

Aitken, Samuel L, et al.. (2023). 356. Impact of CLSI Breakpoint Changes on Unit-Specific Combination Antibiograms for Gram-Negative Respiratory Isolates. Open Forum Infectious Diseases. 10(Supplement_2).

Albin, Owen, Jason M. Pogue, Richard G. Wunderink, & Keith S. Kaye. (2023). Which trial do we need? Combination antimicrobial therapy for hospital-acquired bacterial pneumonia caused by Pseudomonas aeruginosa. Clinical Microbiology and Infection. 30(2). 162–164. 2 indexed citations

10.

McNamara, Sara, et al.. (2023). 2474. Emergence of Candida auris in Michigan. Open Forum Infectious Diseases. 10(Supplement_2).

11.

Pogue, Jason M., et al.. (2023). Executive Summary: State-of-the-Art Review: State of the Management of Infections Caused by Multidrug-Resistant Gram-Negative Organisms. Clinical Infectious Diseases. 77(9). 1223–1225. 2 indexed citations

12.

Monogue, Marguerite L., Emily L. Heil, Samuel L Aitken, & Jason M. Pogue. (2021). The role of tazobactam‐based combinations for the management of infections due to extended‐spectrum β‐lactamase‐producing Enterobacterales: Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 41(10). 864–880. 6 indexed citations

13.

Pogue, Jason M., Adam S. Lauring, Tejal Gandhi, et al.. (2021). Monoclonal Antibodies for Early Treatment of COVID-19 in a World of Evolving SARS-CoV-2 Mutations and Variants. Open Forum Infectious Diseases. 8(7). ofab268–ofab268. 1 indexed citations

14.

Li, Chen, Jason M. Pogue, Varun Sharma, et al.. (2020). Correction: ColistinDose, a Mobile App for Determining Intravenous Dosage Regimens of Colistimethate in Critically Ill Adult Patients: Clinician-Centered Design and Development Study. JMIR mhealth and uhealth. 8(12). e26593–e26593. 1 indexed citations

15.

Li, Chen, Jason M. Pogue, Varun Sharma, et al.. (2020). ColistinDose, a Mobile App for Determining Intravenous Dosage Regimens of Colistimethate in Critically Ill Adult Patients: Clinician-Centered Design and Development Study. JMIR mhealth and uhealth. 8(12). e20525–e20525. 4 indexed citations

16.

Morrisette, Taylor, Thomas P. Lodise, Marc H. Scheetz, et al.. (2020). The Pharmacokinetic and Pharmacodynamic Properties of Hydroxychloroquine and Dose Selection for COVID-19: Putting the Cart Before the Horse. Infectious Diseases and Therapy. 9(3). 561–572. 19 indexed citations

17.

Tsuji, Brian T., Jason M. Pogue, Alexandre Prehn Zavascki, et al.. (2019). International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti‐infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 39(1). 10–39. 637 indexed citations breakdown →

18.

Jorgensen, Sarah C J, Trang D Trinh, Evan J Zasowski, et al.. (2019). 2250. Combination Vancomycin Plus Cefazolin for Methicillin-Resistant Staphylococcus aureus Bloodstream Infections. Open Forum Infectious Diseases. 6(Supplement_2). S769–S769. 6 indexed citations

19.

Morrill, Haley J., Jason M. Pogue, Keith S. Kaye, & Kerry L. LaPlante. (2015). Treatment Options for Carbapenem-Resistant Enterobacteriaceae Infections. Open Forum Infectious Diseases. 2(2). ofv050–ofv050. 320 indexed citations

20.

Malani, Anurag N., et al.. (2015). Antimicrobial Stewardship Practices in Michigan Long-Term Care Facilities. Infection Control and Hospital Epidemiology. 37(2). 236–237. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact